生物制剂在银屑病治疗中的临床实践

Clinical practice of biological agents therapy for psoriasis

银屑病是一种慢性炎症性皮肤病,因其难以治愈、反复发作而对患者的生活带来极大影响。近年来,随着生物制剂的出现和广泛使用,许多对传统治疗应答欠佳的患者有了更多选择。目前已上市并投入临床使用的生物制剂包括肿瘤坏死因子-α(tumor necrosis factor,TNF-α)抑制剂、白细胞介素(interleukin,IL)-12/IL-23抑制剂、IL-17A抑制剂和IL-36抑制剂,以其突出的疗效和稳定的安全性已经为许多银屑病患者带去了可观的病情改善。本文汇总目前主流的11种生物制剂相关真实世界研究,综述其实际疗效、不良反应及注意事项。

Psoriasis is a chronic inflammatory skin disease that greatly affects the lives of patients due to its incurable and recurrent nature.In recent years,with the availability and clinical practice of biologic agents,many patients who failed to respond to traditional treatments have more options.Currently the biologics that have been marketed and put into clinical use include TNF-α(tumor necrosis factor)inhibitors,interleukin(IL)-12/IL-23 inhibitors,IL-17A inhibitors and IL-36 inhibitors,which have brought considerable improvement to many patients with psoriasis due to their outstanding efficacy and stable safety profile.This article provides a review of the eleven mainstream biologic agents and summarizes their actual efficacy,adverse effects and precautions.